Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.
Dato-DXd Does Not Elicit Significant OS Improvement in Previously Treated, Advanced NSCLC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival
Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth
HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies